arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

BioNexus Gene Lab Corp

BGLC
$0.93 ▼ -0.13 (-12.38%) at close
Healthcare ·Services-Medical Laboratories ·USServices-Medical Laboratories
35 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

BioNexus Gene Lab Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth -96.6% ↗
Op. Margin -370.8%
ROIC -3.6% ↗
FCF / Share —
Trailing P/E —
Price / Book 0.3x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 4, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$76.16K
↓ -96.6% —
Net Income Profit after all expenses
$-543.58K
↑ +11.8% —
Operating Margin Operating profit as % of sales
-370.8%
↓ -73.7% 6th
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
7
Returns
21
Financial Health
7
Cash Quality ↑
45

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 9 years · 35 quarters